Fig. 6
From: Drug and disease signature integration identifies synergistic combinations in glioblastoma
JQ1 and alisertib synergize in vitro and in vivo in reducing GBM tumor growth. a Synergistic response of JQ1 and alisertib measured by ATP levels using CellTiter-Glo® in GBM22 PDX cells. ATP levels are normalized to positive control (Velcade) and negative control (DMSO). The Bliss score surface (top) and isobologram plot of the Loewe combination index (bottom). b Synergistic response observed for JQ1 and alisertib combination in vitro in a flank model of GBM, measured by caliper. Mice were implanted with GBM22 PDX cells and treated starting at day 15 with 25 mg kg−1 per day of alisertib and/or 30 mg kg−1 per day of JQ1 for 10 days. Significance was determined using an unpaired t-test with Holm-Sidak correction for multiple comparisons, *p < 0.05, ***p < 0.001. c JQ1 and alisertib combination does not reduce mouse weight. Weight of mice analyzed in (c) was assessed at the indicated time points. Sample size was as follows: DMSO, JQ1 n = 4; Alisertib, Alisertib+JQ1 n = 5. Please note that one mouse in each the Alisertib and Alisertib+JQ1 group perished before 23-day animal weight was obtained. Mean and standard error bars are shown. Source data can be found in the Source Data file, Supplementary Data 6, under tab Fig. 6
